Doctors say HRT can ease scores of midlife symptoms beyond hot flushes

Hormone replacement therapy (HRT) can relieve a wide range of symptoms linked to falling oestrogen levels in midlife, not only the well-known hot flushes and night sweats, according to clinicians and a new book by Dr. Ellie Cannon.

Dr. Cannon, a general practitioner and author, says medical literature lists more than 30 symptoms associated with declining oestrogen that may improve with appropriate HRT. She describes patients who sought help for persistent problems such as recurrent urinary tract infections, joint pain, headaches and palpitations — issues they and some clinicians had not immediately recognised as possibly menopausal.

In a case she recounts, a 54-year-old woman who had repeated bladder infections saw symptom improvement after being prescribed topical vaginal oestrogen. Dr. Cannon said the treatment strengthened thinning vulvovaginal and urethral tissues and helped restore a barrier to infection. Within weeks the soreness settled and infections became less frequent, she wrote.

The menopause typically occurs between ages 45 and 55 as oestrogen and progesterone levels fall and periods cease. Classic symptoms include hot flushes, night sweats, poor sleep, mood changes, reduced libido and vaginal dryness. Dr. Cannon and other clinicians emphasise that hormonal change can also produce less obvious problems: aching or stiff joints, some types of headaches, dizziness, heart palpitations and cognitive changes often described as "brain fog." Those complaints are frequently attributed to aging, stress or other conditions, which can delay consideration of HRT.

Use of HRT on the NHS has risen markedly over the past decade, from an estimated 1 million women to roughly 2.6 million, Dr. Cannon writes, a trend she links to greater public discussion, celebrity testimony and social media. Research cited by her suggests about four in 10 women are not sufficiently troubled by menopausal symptoms to seek treatment.

HRT is available in several forms, including systemic tablets, transdermal patches and gels, and local preparations such as vaginal oestrogen. Dr. Cannon notes that tablets carry a small increased risk of blood clots, while transdermal patches and gels do not appear to share that increased clotting risk. A past history of certain cancers or other medical conditions may change the balance of risks and benefits, and clinicians should tailor recommendations to each patient.

There is no single laboratory test that confirms the need for HRT; diagnosis and treatment decisions are typically clinical and based on symptoms, history and physical examination. Dr. Cannon and other medical sources recommend that women with persistent, unexplained midlife symptoms seek evaluation by a general practitioner so other causes such as thyroid disease, anaemia, cardiological conditions or musculoskeletal disorders can be assessed and ruled out.

Experts caution that HRT is not a panacea. It will not stop ageing or serve as a cosmetic fix, and some symptoms in midlife are driven by life stresses, caregiving responsibilities or other non-hormonal causes. Nonetheless, for many women whose problems are linked to declining oestrogen, appropriate HRT can produce substantial and lasting symptom relief.

Dr. Cannon's account, including clinical examples and discussion of indications and risks, is presented in her new book, The Little Book Of HRT. The book and clinicians' statements aim to broaden understanding of how the menopause can present and to encourage conversations between patients and clinicians about whether hormone therapy might be an appropriate option.

As awareness of the range of menopause-related symptoms grows, primary care clinicians say timely assessment and shared decision-making remain essential. Women aged about 40 to 65 with persistent, unexplained symptoms are advised to consult their GP to determine whether hormonal change could be contributing and to consider the relative benefits and risks of available treatments.